Alligator Bioscience AB (ATORX)

Currency in SEK
5.7660
+0.0150(+0.26%)
Closed·
ATORX Scorecard
Full Analysis
Quickly burning through cash
ATORX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.60005.9900
52 wk Range
0.00667.4000
Key Statistics
Prev. Close
5.751
Open
5.99
Day's Range
5.6-5.99
52 wk Range
0.0066-7.4
Volume
282.92K
Average Volume (3m)
414.98K
1-Year Change
4,682.36%
Book Value / Share
-1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATORX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Alligator Bioscience AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Neutral
Moving Averages
Strong Buy

Alligator Bioscience AB Company Profile

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.

Alligator Bioscience AB Earnings Call Summary for Q2/2025

  • Q2 2025: 22M USD operating loss, 4M USD operational costs; stock fell 4.43% to 6.14 USD post-earnings
  • Metazolumab ready for Phase III trials; HLX22 received EU orphan designation with 10B USD potential peak sales
  • Cost reduction target of 20-25M SEK per quarter in H2 2025; current liquidity ~24M USD
  • CEO highlights Metazolumab's mechanism of action; CFO assures financial flexibility through 2025
  • InvestingPro projects profitability in 2025 with 0.01 USD EPS forecast; stock appears undervalued despite 97.3% 6-month decline
Last Updated: 10/07/2025, 14:58
Read Full Transcript

Compare ATORX to Peers and Sector

Metrics to compare
ATORX
Peers
Sector
Relationship
P/E Ratio
−1.5x−4.8x−0.5x
PEG Ratio
−0.02−0.190.00
Price/Book
−5.8x3.7x2.6x
Price / LTM Sales
4.6x22.2x3.2x
Upside (Analyst Target)
229.5%29.1%45.7%
Fair Value Upside
Unlock12.7%8.6%Unlock

Earnings

Latest Release
Jul 10, 2025
EPS / Forecast
-0.08 / --
Revenue / Forecast
345.00K / --
EPS Revisions
Last 90 days

ATORX Income Statement

FAQ

What Stock Exchange Does Alligator Bioscience Trade On?

Alligator Bioscience is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for Alligator Bioscience?

The stock symbol for Alligator Bioscience is "ATORX."

What Is the Alligator Bioscience Market Cap?

As of today, Alligator Bioscience market cap is 200.68M.

What Is Alligator Bioscience's Earnings Per Share (TTM)?

The Alligator Bioscience EPS (TTM) is -17.16.

When Is the Next Alligator Bioscience Earnings Date?

Alligator Bioscience will release its next earnings report on 22 Oct 2025.

From a Technical Analysis Perspective, Is ATORX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alligator Bioscience Stock Split?

Alligator Bioscience has split 2 times.

How Many Employees Does Alligator Bioscience Have?

Alligator Bioscience has 15 employees.

What is the current trading status of Alligator Bioscience (ATORX)?

As of 02 Aug 2025, Alligator Bioscience (ATORX) is trading at a price of 5.77, with a previous close of 5.75. The stock has fluctuated within a day range of 5.60 to 5.99, while its 52-week range spans from 0.01 to 7.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.